Skip to contentR
Revolution Medicines, Inc.
R
RVMDWRevolution Medicines, Inc. Q3 2025 · 10-Q
Revenue—
Net Income-$305.21M-$305.21MN/M vs Q3 2024 EPS Diluted-$1.61-$1.61N/M vs Q3 2024 Operating Income-$315,269,000N/M Operating Cash Flowderived-$207,311,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
Free Cash Flowderived-$210,660,000N/M ended Sep 30, 2025 · filed Nov 5, 2025 · 36 d after period end